ArticleThe Prostate2010
New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.
Article in The Prostate, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- ALDH1L2 induces resistance to chemotherapy in small cell lung cancer by inhibiting ferroptosis.Redox biology · 2026Article
- Oncogenic role of FOXM1 in human prostate cancer (Review).Oncology reports · 2024Review
- Dual Akt and Bcl-2 inhibition induces cell-type specific modulation of apoptotic and autophagic signaling in castration resistant prostate cancer cell lines.Molecular biology reports · 2021Article
- BH3-mimetics: recent developments in cancer therapy.Journal of experimental & clinical cancer research : CR · 2021Review
- Comprehensive Analysis of Cell Cycle-Related Genes in Patients With Prostate Cancer.Frontiers in oncology · 2021Article
- TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21/FoxM1.Journal of experimental & clinical cancer research : CR · 2020Article
- Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer.OncoTargets and therapy · 2020Review
- Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning.EBioMedicine · 2019Article
- BH3 Mimetics for the Treatment of Prostate Cancer.Frontiers in pharmacology · 2017Article
- MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Review
- The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.International journal of oncology · 2013Article
- Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.Clinical genitourinary cancer · 2013Review
- The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer.Journal of molecular medicine (Berlin, Germany) · 2013Article
- Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.Cancer biology & therapy · 2012Article
- Targeting Mcl-1 for the therapy of cancer.Expert opinion on investigational drugs · 2011Review
- Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737.Cellular oncology (Dordrecht, Netherlands) · 2011Article
- Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells.PloS one · 2011Article
- Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells.Journal of cellular biochemistry · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundWe previously described the identification of a transcriptional inhibitor ARC and FoxM1 inhibitors, thiazole antibiotics, Siomycin A and thiostrepton that were able to induce potent p53-independent apoptosis in cancer cell lines of different origin. Here, we report the characterization of these drugs individually or in combination with ABT-737 and bortezomib on a panel of prostate cancer cell lines.
methodsDU 145, LNCaP and PC-3 prostate cancer cells were treated with ARC, Siomycin A and thiostrepton to evaluate their activity as single agents or in combination with ABT-737 and bortezomib to measure their synergistic potential in anti-proliferative and cell cycle assays. Chou-Talalay method was used to quantitate the synergistic interaction. Western blot method was used to determine Mcl-1 and FoxM1 expression and caspase-3 cleavage.
resultsWe show that ARC inhibited the viability of prostate cancer cells and induced apoptosis in low nanomolar concentration. It potently downregulated the expression of Mcl-1 and showed synergistic combination effect with Bcl-2 inhibitor ABT-737. Thiazole antibiotics, Siomycin A and thiostrepton inhibited growth, FoxM1 expression and induced cell death in prostate cancer cells in low micromolar concentrations. In addition, thiostrepton and ARC synergistically induced apoptosis in prostate cancer cells following combination treatment with proteasome inhibitor bortezomib. Furthermore, we found that all tested drug combinations were able to induce apoptosis selectively in transformed, but not normal cells of the same origin.
conclusionsBased on their in vitro activity as single or combination agents, ARC, Siomycin A and thiostrepton represent potential candidates for drug development against prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.